Zuellig Pharma Launches Lilly's Obesity and Diabetes Medicine in Thailand
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country.
Launched Eli Lilly's Mounjaro® (tirzepatide) for obesity and diabetes in Thailand.
Zuellig Pharma has launched Eli Lilly's innovative obesity and diabetes medicine, Mounjaro® (tirzepatide), in Thailand. This marks a significant step in providing advanced treatment options for patients managing these chronic conditions, leveraging Zuellig Pharma's expertise in bringing novel pharmaceuticals to the Thai market and improving patient care.
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country. This aligns with regional efforts to combat the rising prevalence of these metabolic diseases, offering improved patient outcomes and quality of life through access to innovative treatments.
This product launch in Thailand addresses the significant and growing burden of obesity and diabetes in the APAC region, offering a new treatment option for patients.
Where this signal fits in the broader landscape.
Zuellig Pharma Acquires Zam-Buk and Vapex Brands from Bayer
Zuellig Pharma Expands Lundbeck Partnership for Neuro-Psychiatric Solutions
Zuellig Pharma Opens Clinical Trial Support Innovation Center in South Korea
Zuellig Pharma Opens Clinical Trial Support Center in South Korea
Zuellig Pharma and Organon Partner for Women's Health in Myanmar
https://www.zuelligpharma.com/news-insights/zuellig-pharma-launches-lillys-innovative-obesity-and-diabetes-medicine-in-thailand
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인